The Motley Fool

Can you afford to overlook this solid-looking growth and dividend stock?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image of person checking their shares portfolio on mobile phone and computer
Image source: Getty Images.

The Bioventix (LSE: BVXP) share price looks a little shaky today following the release of the antibody developer’s full-year results report. In fact, after peaking in April near 4,000p, the stock is down almost 14% at the current 3,456p, as I write.

Long may the ‘correction’ continue, I say, because although the enterprise displays stunning metrics relating to quality, I feel that the valuation had been getting ahead of itself. For example, the forward-looking earnings multiple for the current trading year to June 2020 is running just over 27.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Good figures

The underlying figures in this report are pretty good, as we’ve become used to. Turnover increased by just over 16% compared to the year before and profit before tax moved more than 14% higher. I reckon it’s worth focusing on the underlying figures because a one-off, back-dated royalty payment flattered last years results making today’s headline comparisons look weak — and the financial outcome here is not weak at all in reality.

However, City analysts following the firm don’t expect earnings to expand in the years ahead any faster than today’s outcome indicates. Because of that, I reckon there’s scope for a valuation down-rating. And if that happened, I’d be a keen buyer of the shares.

Yet I can’t ignore the firm’s robust and defensive-looking business model. A small team of 12 full-time equivalents toils daily to research, develop and commercially supply high-affinity monoclonal antibodies for use on blood-testing machines used by hospitals and other labs around the world.

As well as income from selling physical antibodies, Bioventix earns around 70% of its annual revenue from royalties generated when its customers resell diagnostic products incorporating Bioventix antibodies to their downstream end-users.

I like two things about the set-up. Firstly, those revenues work on a royalty system, which means they are uncapped and linked to the usage of the product. Secondly, that the sector strikes me as being un-correlated to general macroeconomic conditions, which means the cash flowing into the business is likely to remain steady.

Sticky revenues

Indeed, it takes between four and 10 years before the firm’s initial research work generates royalties because of the long development and approvals process required. One consequence of this is that “there is a natural continuity of use as a result of a reluctance by a customer to change from one antibody to another.”

And the prospect of steady cash inflow leads to decent dividends for shareholders, which Bioventix demonstrates in its dividend record. Ordinary dividend payments are around 200% higher than they were five years ago, and on top of that, the company announced a special dividend today of 47p. Without the special dividend, the yield stands at about 2.1% and with the special, it is around 3.5%.

I think the company is a decent bet for long-term growth and dividend income, and I’d be a buyer of the shares if the market knocks the valuation lower from where it is now. This one’s on my radar, and I’m poised to pounce!

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended Bioventix. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.